Outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequence in post-docetaxel (DOC) setting: final analysis from a multicenter Italian study - Caffo, O; Bria, E; Giorgi, U D (ASCO J Clin Oncol, 2017)
et al.